Wockhardt Limited
4,255words
0turns
0analyst exchanges
0executives
Key numbers — 28 extracted
rs,
OCK/SEC/SE/2023-24/072 26th February, 2024 BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 National Stock Exchange of India Limited Listing Department Excha
INR 2,129
a violation of applicable securities law 2 Snapshot of Wockhardt Net sales Revenues (9M FY24) INR 2,129 Cr. 12 manufacturing facilities across world EBITDA (9M FY24) INR 173 Cr. Net Debt: Equity Ratio
INR 173
les Revenues (9M FY24) INR 2,129 Cr. 12 manufacturing facilities across world EBITDA (9M FY24) INR 173 Cr. Net Debt: Equity Ratio (as on September 30, 2023) International Business (9M FY24) 0.27x* 7
0.27x
INR 173 Cr. Net Debt: Equity Ratio (as on September 30, 2023) International Business (9M FY24) 0.27x* 78% e r u t c u r t s a r f n I 2 R&D centres one each in India, UK ~ 315 scientists with 55 P
78%
Cr. Net Debt: Equity Ratio (as on September 30, 2023) International Business (9M FY24) 0.27x* 78% e r u t c u r t s a r f n I 2 R&D centres one each in India, UK ~ 315 scientists with 55 PhD’s;
36%
structuring - facility shutdown ► Shift to third party manufacturing ► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribut
21%
turing - facility shutdown ► Shift to third party manufacturing ► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribution
22%
g - facility shutdown ► Shift to third party manufacturing ► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribution for 9
6%
facility shutdown ► Shift to third party manufacturing ► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribution for 9M FY
9%
third party manufacturing ► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribution for 9M FY23 -24 4 Financial Highlight
2023
%
► Defocusing Pharma R&D 36% 21% 22% 6% 6% *9M FY 23-24 (Others: 9%) **as on 31st December 2023 % sales revenue contribution for 9M FY23 -24 4 Financial Highlights Net Sales Revenues INR Cr. E
7%
hlights Net Sales Revenues INR Cr. EBITDA INR Cr. 307 328 3,239 489 2,840 130 2,693 26 7% growth 2,129 5 1,983 24 2,710 2,750 2,667 1,959 2,124 71 98 80% growth 173 5 16